Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers.
OBJECTIVE
Oral anticholinergic drugs, such as oxybutynin, are often used in the treatment of hyperhidrosis, but few studies have focused on dosing strategies for children. The objective was to assess the effectiveness and safety of individualized dosing regimens of oral oxybutynin for treating primary focal hyperhidrosis (PFH) in children and teenagers.


METHODS
A prospective study was performed including patients who initiated treatment for hyperhidrosis between November 2011 and November 2014. Response to treatment and adverse effects were evaluated using the Hyperhidrosis Disease Severity Scale at baseline and at 3 and 12 months.


RESULTS
Of 16 patients included in the study, 15 (93.8%) had responded to treatment at the 3-month follow-up (62.5% with excellent response). At the 12-month follow-up, the 11 patients who continued the treatment were still responding (63.6% with excellent response). Adverse effects were reported for 68.8% of the patients at 3 months and 54.5% at 12 months, with a predominance of oropharyngeal xerosis. No serious adverse effects were observed.


CONCLUSIONS
Dose individualization of oral oxybutynin according to clinical response and tolerance observed in each patient is a useful management strategy in children and teenagers.
Dermatology Department, Hospital Costa del Sol, Marbella, Spain.
Javier
J
Del Boz
Dermatology Department, Hospital Costa del Sol, Marbella, Spain.
José Francisco
JF
Millán-Cayetano
Dermatology Department, Hospital Costa del Sol, Marbella, Spain.
Nuria
N
Blázquez-Sánchez
Dermatology Department, Hospital Costa del Sol, Marbella, Spain.
Magdalena
M
de Troya
D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006945:Hyperhidrosis / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D008333:Mandelic Acids / Q000008:administration & dosage*; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D057285:Precision Medicine; D011446:Prospective Studies; D011788:Quality of Life; D012720:Severity of Illness Index; D016896:Treatment Outcome
D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin